The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets

• Main Authors: Yutaro Ohno (Author), Eri Okita (Author), Mika Kawai-Uchida (Author), Youji Shoukei (Author), Kazuhiro Soshiroda (Author), Tomoyuki Kanda (Author), Shinichi Uchida (Author)
• Formato: Libro
• Publicado: Elsevier, 2023-07-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

The adenosine A2A receptor antagonist/inverse agonist, KW-6356 has been shown to be effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to L-3,4-dihydroxyphenylalanine (L-DOPA)/decarboxylase inhibitor. However, the effects of KW-6356 combined with L-DOPA on a...